vimarsana.com

Latest Breaking News On - ப்ரோமிதெயௌஸ் உயிர் அறிவியல் இன்க் - Page 1 : vimarsana.com

Prometheus Biosciences to Host Virtual R&D Day for

Prometheus Biosciences to Host Virtual R&D Day for
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

3 Small Cap Stocks That Are Short Squeeze Candidates

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme. A stock s float is the number of shares that trade freely on the public market. Because insiders and institutional investors don’t typically trade their shares on a daily basis, those shares don’t typically contribute to a stock s near-term liquidity. Float is the number of shares that remain after accounting for insider and institutional ownership. Why Is It Important? When a stock gains positive momentum in the market, momentum buyers can rush in all at once. If a stock has a high short interest, short covering can quickly ramp up demand for shares, triggering a short squeeze. Since low float stocks have relatively few shares trading freely, a major imbalance in supply and demand can serve as rocket fuel for the share price.

3 Short Squeeze Candidates In The Health Care Sector

Prometheus Biosciences Inc (NASDAQ:RXDX) Prometheus Biosciences is a biotechnology company focused on therapies and diagnostic products for the treatment of inflammatory bowel disease (IBD). The stock completed its IPO in March and is also the perfect short squeeze candidate within the sector. Prometheus’ 970,000-share float is minuscule, creating plenty of opportunity for extreme volatility if trading volume rises. Prometheus also has 30.2% of its float held short, a fairly high short percent of float. Finally, the stock has already demonstrated its potential for extreme volatility. In about two months on the market, Prometheus shares have already swung from its IPO price of $19 all the way up to $28.33 in March, back down to $16.11 a couple of weeks later, back up to $30.62 in mid-April and then back down to $21.84 on Thursday.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.